Emcure Pharmaceuticals Q4 Results
- BSE: 544210
- NSE: EMCURE
- ISIN: INE168P01015
- Sector: Biotechnology & Drugs
BSE
1,820.50
10.05 (0.56%)
10.05 (0.56%)Volume707.00
Updated: Mon 13 Jul, 2026 | 11:24:30
NSE
1,820.205.80 (0.32%)
5.80 (0.32%)Volume23.80 K
Updated: Mon 13 Jul, 2026 | 11:09:42
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹2,469.70 Cr.(16.70%)
- Operating Profit₹346.64 Cr.(22.62%)
- Profit After Tax₹243.40 Cr.(28.81%)
- Operating Margin14.04%(5.07%)
Note: Comparison is on YoY basis
Quarterly - Emcure Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 2,123.06 | 2,046.19 | 3.76% | 1,550.71 | 15.79% |
| Depreciation/ Amortization | 106.27 | 104.68 | 1.52% | 90.56 | 9.74% |
| Operating Income | 346.64 | 317.29 | 9.25% | 220.65 | 22.62% |
| Net Income | 243.40 | 230.54 | 5.58% | 115.17 | 28.81% |
| Other Operating Expenses Total | 637.23 | 553.60 | 15.11% | 450.50 | 38.27% |
| Net Income Before Taxes | 341.18 | 313.79 | 8.73% | 166.90 | 30.91% |
| Total Revenue | 2,469.70 | 2,363.48 | 4.49% | 1,771.36 | 16.70% |
| Selling/ General/ Admin Expenses Total | 386.78 | 387.33 | -0.14% | 338.51 | 3.59% |
| Diluted Normalized EPS | 12.45 | 13.64 | -8.74% | 5.39 | 19.85% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.